Federal Register of Legislation - Australian Government

Primary content

PB 119 of 2008 Determinations/Health as amended, taking into account amendments up to National Health Determination under paragraph 98C(1)(b) Amendment 2018 (No. 1) (PB 3 of 2018)
This Determination provides for the conditions under which payments will be made in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners and repeals the National Health Act 1953 - Determination under paragraph 98C(1)(b) - conditions (No. PB 79 of 2008).
Administered by: Health
Registered 01 Feb 2018
Start Date 01 Feb 2018
End Date 28 Feb 2018

Commonwealth Coat of Arms of Australia

Determination—Conditions (PB 119 of 2008)

made under paragraph 98C(1)(b) of the

National Health Act 1953

Compilation No. 81

Compilation date:                           1 February 2018

Includes amendments up to:         PB 3 of 2018

Registered:                                      1 February 2018

 

About this compilation

This compilation

This is a compilation of the Determination—Conditions (PB 119 of 2008) that shows the text of the law as amended and in force on 1 February 2018 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Determination–Conditions (PB 119 of 2008)

Definitions

3.       “Act” means the National Health Act 1953;

“approved ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;

“Commonwealth price” has the same meaning as in subsection 84(1) of the Act;

“extemporaneously‑prepared pharmaceutical benefit” means a pharmaceutical benefit other than a ready‑prepared pharmaceutical benefit;

“pack quantity” has the same meaning as in subsection 84(1) of the Act;

“prescription” includes a prescription written on an authority prescription made under regulation 13 of the Regulations, a prescription required to be submitted to the Chief Executive Medicare for the purposes of a determination made under subsection 85(2A) or subsection 85A(2) of the Act, a repeat authorisation, or a deferred supply authorisation;

“proportional ex‑manufacturer price” has the same meaning as in subsection 84(1) of the Act;

“ready‑prepared pharmaceutical benefit” means a listed brand of a pharmaceutical item;

“Regulations” means the National Health (Pharmaceutical Benefits) Regulations 1960 made under the Act;

“standard formula preparation” means an extemporaneously‑prepared pharmaceutical benefit that is listed in Schedule 5 to this Determination.

Schedules

4.       For the supply of pharmaceutical benefits:

(a)     pharmaceutical benefits that involve the admixture of ready‑prepared ingredients are set out in Schedule 1;

(b)     drugs that are used in the preparation of extemporaneously‑prepared pharmaceutical benefits and that are unstable or packed sterile and unused quantities of which are unsuitable for future use are set out in Schedule 2;

(c)     pharmaceutical benefits that are classified as dangerous drugs for the purpose of payment of a dangerous drug fee are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 3 to this Determination;

(d)     pharmaceutical benefits the complete pack of which shall be supplied regardless of any lesser quantity ordered are pharmaceutical benefits that have the pharmaceutical items which have the listed drug in the form set out in Schedule 4.

Brand identified

5.       Where a prescription identifies the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of that brand.

Brand not identified

6.       Where a prescription does not identify the ready‑prepared pharmaceutical benefit to be supplied by reference to a particular brand, the amount payable shall be based on the approved ex‑manufacturer price or proportional ex‑manufacturer price for a pack quantity of the brand of that benefit, being a brand which is available from a wholesale source in the capital city of the State in which the benefit is supplied, for which the Commonwealth price for the supply of the benefit is lowest.

Packs

7.       Where a prescription calls for a quantity of one of the pharmaceutical benefits that have the pharmaceutical items which have the form of the listed drug set out in Schedule 4 that is less than the quantity contained in the size of unit included in the particulars specified in the column headed 'Form' in that Schedule in relation to that benefit, the complete pack shall be supplied.

Variation of medicinal preparation

8.       A medicinal preparation that is a variation of a standard formula preparation, due to the addition or deletion of an ingredient or to variation of the dose, or that is a combination of standard formula preparations, shall be deemed not to be a standard formula preparation.

Election—extemporaneously-prepared pharmaceutical benefits

9.       An election made pursuant to section 31 of the determination made under paragraph 98B(1)(a) of the Act shall be made in writing to the Chief Executive Medicare and shall remain in force for a period of not less than 3 months from and including the date of election, but may be revoked in writing at any time after the expiration of that period; and while the election remains in force, the amount payable to the approved pharmacist or approved medical practitioner, in respect of the supply of an extemporaneously‑prepared pharmaceutical benefit that is not a standard formula preparation, shall be the amount calculated in accordance with section 18 of the determination made under paragraph 98B(1)(a) of the Act.


SCHEDULE 1—PHARMACEUTICAL BENEFITS THAT INVOLVE THE ADMIXTURE OF READY‑PREPARED INGREDIENTS

Listed Drug

Form (strength, type, size, etc.)

Amoxycillin with Water – Purified BP

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

 

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

 

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

 

Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL

Amoxycillin with Clavulanic Acid and Water – Purified BP

Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL

Azithromycin with Water – Purified BP

Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL

Cefaclor with Water – Purified BP

Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

Cefuroxime with Water Purified BP

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL

Cephalexin with Water – Purified BP

Granules for oral suspension 125 mg per 5 mL, 100 mL

Granules for oral suspension 250 mg per 5 mL, 100 mL

Clarithromycin with Water – Purified BP

Powder for oral liquid 250 mg per 5 mL, 50 mL

Erythromycin with Water – Purified BP

Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL

Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL

Flucloxacillin with Water – Purified BP

Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL

Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL

Fluconazole with Water – Purified BP

Powder for oral suspension 50 mg in 5 mL, 35 mL

Mycophenolic Acid with Water – Purified BP

Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL

Phenoxymethylpenicillin with Water – Purified BP

Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL

Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL

Valganciclovir

Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL

Voriconazole with Water—Purified BP

Powder for oral suspension 40 mg per mL, 70 mL

 

SCHEDULE 2—DRUGS THAT ARE USED IN THE PREPARATION OF EXTEMPORANEOUSLY‑PREPARED PHARMACEUTICAL BENEFITS AND THAT ARE UNSTABLE OR PACKED STERILE AND UNUSED QUANTITIES OF WHICH ARE UNSUITABLE FOR FUTURE USE

Listed Drug

Form (strength, type, size, etc.)

Water For Injections—sterilised BP


SCHEDULE 3—PHARMACEUTICAL BENEFITS THAT ARE CLASSIFIED AS DANGEROUS DRUGS FOR THE PURPOSE OF PAYMENT OF A DANGEROUS DRUG FEE

Listed Drug

Form (strength, type, size, etc.)

Alprazolam

Tablet 250 micrograms

 

Tablet 500 micrograms

 

Tablet 1 mg

Buprenorphine

Transdermal patch 5 mg

 

Transdermal patch 10 mg

 

Transdermal patch 15 mg

 

Transdermal patch 20 mg

 

Transdermal patch 25 mg

 

Transdermal patch 30 mg

 

Transdermal patch 40 mg

Codeine

Tablet containing codeine phosphate 30 mg

Dexamphetamine

Tablet containing dexamphetamine sulfate 5 mg

Fentanyl

Lozenge 200 micrograms (as citrate)

 

Lozenge 400 micrograms (as citrate)

 

Lozenge 600 micrograms (as citrate)

 

Lozenge 800 micrograms (as citrate)

 

Lozenge 1200 micrograms (as citrate)

 

Lozenge 1600 micrograms (as citrate)

 

Tablet (orally disintegrating) 100 micrograms (as citrate)

 

Tablet (orally disintegrating) 200 micrograms (as citrate)

 

Tablet (orally disintegrating) 400 micrograms (as citrate)

 

Tablet (orally disintegrating) 600 micrograms (as citrate)

 

Tablet (orally disintegrating) 800 micrograms (as citrate)

 

Tablet (sublingual) 100 micrograms (as citrate)

 

Tablet (sublingual) 200 micrograms (as citrate)

 

Tablet (sublingual) 300 micrograms (as citrate)

 

Tablet (sublingual) 400 micrograms (as citrate)

 

Tablet (sublingual) 600 micrograms (as citrate)

 

Tablet (sublingual) 800 micrograms (as citrate)

 

Transdermal patch 1.28 mg

 

Transdermal patch 2.063 mg

 

Transdermal patch 2.1 mg

 

Transdermal patch 2.55 mg

 

Transdermal patch 4.125 mg

 

Transdermal patch 4.2 mg

 

Transdermal patch 5.10 mg

 

Transdermal patch 7.65 mg

 

Transdermal patch 8.25 mg

 

Transdermal patch 8.4 mg

 

Transdermal patch 10.20 mg

 

Transdermal patch 12.375 mg

 

Transdermal patch 12.6 mg

 

Transdermal patch 16.5 mg

 

Transdermal patch 16.8 mg

Hydromorphone

Tablet containing hydromorphone hydrochloride 2 mg

 

Tablet containing hydromorphone hydrochloride 4 mg

 

Tablet containing hydromorphone hydrochloride 8 mg

 

Tablet (modified release) containing hydromorphone hydrochloride 4 mg

 

Tablet (modified release) containing hydromorphone hydrochloride 8 mg

 

Tablet (modified release) containing hydromorphone hydrochloride 16 mg

 

Tablet (modified release) containing hydromorphone hydrochloride 32 mg

 

Tablet (modified release) containing hydromorphone hydrochloride 64 mg

 

Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 473 mL

 

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

 

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Lisdexamfetamine

Capsule containing lisdexamfetamine dimesilate 30 mg

 

Capsule containing lisdexamfetamine dimesilate 50 mg

 

Capsule containing lisdexamfetamine dimesilate 70 mg

Methadone

Tablet containing methadone hydrochloride 10 mg

 

Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL

 

Injection containing methadone hydrochloride 10 mg in 1 mL

Methylphenidate

Tablet containing methylphenidate hydrochloride 10 mg

 

Tablet containing methylphenidate hydrochloride 18 mg (extended release)

 

Tablet containing methylphenidate hydrochloride 27 mg (extended release)

 

Tablet containing methylphenidate hydrochloride 36 mg (extended release)

 

Tablet containing methylphenidate hydrochloride 54 mg (extended release)

 

Capsule containing methylphenidate hydrochloride 20 mg (modified release)

 

Capsule containing methylphenidate hydrochloride 30 mg (modified release)

 

Capsule containing methylphenidate hydrochloride 40 mg (modified release)

Morphine

Tablet containing morphine sulfate 10 mg

 

Tablet containing morphine sulfate 20 mg

 

Tablet containing morphine sulfate 30 mg

 

Tablet containing morphine sulfate 5 mg (controlled release)

 

Tablet containing morphine sulfate 10 mg (controlled release)

 

Tablet containing morphine sulfate 15 mg (controlled release)

 

Tablet containing morphine sulfate 30 mg (controlled release)

 

Tablet containing morphine sulfate 60 mg (controlled release)

 

Tablet containing morphine sulfate 100 mg (controlled release)

 

Tablet containing morphine sulfate 200 mg (controlled release)

 

Capsule containing morphine sulfate 10 mg (containing sustained release pellets)

 

Capsule containing morphine sulfate 20 mg (containing sustained release pellets)

 

Capsule containing morphine sulfate 30 mg (controlled release)

 

Capsule containing morphine sulfate 50 mg (containing sustained release pellets)

 

Capsule containing morphine sulfate 60 mg (controlled release)

 

Capsule containing morphine sulfate 90 mg (controlled release)


 

Capsule containing morphine sulfate 100 mg (containing sustained release pellets)

 

Capsule containing morphine sulfate 120 mg (controlled release)

 

Sachet containing controlled release granules for oral suspension, containing morphine sulfate 20 mg per sachet

 

Sachet containing controlled release granules for oral suspension, containing morphine sulfate 30 mg per sachet

 

Sachet containing controlled release granules for oral suspension, containing morphine sulfate 60 mg per sachet

 

Sachet containing controlled release granules for oral suspension, containing morphine sulfate 100 mg per sachet

 

Sachet containing controlled release granules for oral suspension, containing morphine sulfate 200 mg per sachet

 

Oral solution containing morphine hydrochloride 2 mg per mL, 200 mL

 

Oral solution containing morphine hydrochloride 5 mg per mL, 200 mL

 

Oral solution containing morphine hydrochloride 10 mg per mL, 200 mL

 

Injection containing morphine hydrochloride 10 mg in 1 mL

 

Injection containing morphine hydrochloride 20 mg in 1 mL

 

Injection containing morphine hydrochloride 50 mg in 5 mL

 

Injection containing morphine hydrochloride 100 mg in 5 mL

 

Injection containing morphine sulfate 10 mg in 1 mL

 

Injection containing morphine tartrate 120 mg in 1.5 mL

 

Injection containing morphine sulfate 15 mg in 1 mL

 

Injection containing morphine sulfate 30 mg in 1 mL

Oxycodone

Tablet containing oxycodone hydrochloride 5 mg

 

Capsule containing oxycodone hydrochloride 5 mg

 

Capsule containing oxycodone hydrochloride 10 mg

 

Capsule containing oxycodone hydrochloride 20 mg

 

Oral solution containing oxycodone hydrochloride 1 mg per mL, 250 mL

 

Tablet containing oxycodone hydrochloride 10 mg (controlled release)

 

Tablet containing oxycodone hydrochloride 15 mg (controlled release)

 

Tablet containing oxycodone hydrochloride 20 mg (controlled release)

 

Tablet containing oxycodone hydrochloride 30 mg (controlled release)

 

Tablet containing oxycodone hydrochloride 40 mg (controlled release)

 

Tablet containing oxycodone hydrochloride 80 mg (controlled release)

 

Suppository 30 mg (as pectinate)

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg

 

Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg

Tapentadol

Tablet (modified release) 50 mg (as hydrochloride)

 

Tablet (modified release) 100 mg (as hydrochloride)

 

Tablet (modified release) 150 mg (as hydrochloride)

 

Tablet (modified release) 200 mg (as hydrochloride)

 

Tablet (modified release) 250 mg (as hydrochloride)

 

SCHEDULE 4—PHARMACEUTICAL BENEFITS THE COMPLETE PACK OF WHICH SHALL BE SUPPLIED REGARDLESS OF ANY LESSER QUANTITY ORDERED

Listed Drug

Form (strength, type, size, etc.)

Aciclovir

Eye ointment 30 mg per g, 4.5 g

Aclidinium

Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses

Aclidinium with eformoterol

Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses

Adapalene with benzoyl peroxide

Gel 1 mg‑25 mg per g, 30 g

Alendronic acid with colecalciferol and calcium

Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate)

Amino acid formula with fat, carbohydrate, without phenylalanine

Tablet: modified release, 70.8 g protein per 100 g, 110 g (PKU Easy Microtabs)

Amoxycillin

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

 

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

 

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

 

Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL

Amoxycillin with Clavulanic Acid

Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL

Apraclonidine

Eye drops 5 mg (as hydrochloride) per mL, 10 mL

Atenolol

Oral solution 50 mg in 10 mL, 300 mL

Atovaquone

Oral suspension 750 mg per 5 mL, 210 mL

Atropine

Eye drops containing atropine sulfate 10 mg per mL, 15 mL

Azithromycin

Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL

Beclomethasone

Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation)

 

Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation)

 

Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation)

 

Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation)

Benzydamine

Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL

Betaine

Oral powder 180 g

Betaxolol

Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL

Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL

Bimatoprost

Eye drops 300 micrograms per mL, 3 mL

 

Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30

Bimatoprost with timolol

Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL

 

Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30

Bisacodyl

Enemas 10 mg in 5 mL, 25

Brimonidine

Eye drops containing brimonidine tartrate 1.5 mg per  mL, 5 mL

 

Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL

Brimonidine with Timolol

Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL

Brinzolamide

Eye drops 10 mg per mL, 5 mL

Brinzolamide with brimonidine

Eye drops 10 mg brinzolamide and 2 mg brimonidine tartarate per mL, 5 mL

Brinzolamide with Timolol

Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL

Budesonide

Nebuliser suspension 500 micrograms in 2 mL single dose units, 30

 

Nebuliser suspension 1 mg in 2 mL single dose units, 30

 

Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses

 

Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 oses

 

Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses

Budesonide with Eformoterol

Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses

Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses

 

Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

Calcipotriol with betamethasone

Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g

 

Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g

 

Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g

 

Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g

Captopril

Oral solution 5 mg per mL, 95 mL

Carbamazepine

Oral suspension 100 mg per 5 mL, 300 mL

Carbomer

Eye gel 2 mg per g, 10 g

Carmellose

Eye drops containing carmellose sodium 5 mg per mL, 15 mL

 

Eye drops containing carmellose sodium 10 mg per mL, 15 mL

Carmellose with glycerin

Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL

Carmustine

Implants 7.7 mg, 8

Cefaclor

Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL

Cephalexin

Granules for oral suspension 125 mg per 5 mL, 100 mL

Granules for oral suspension 250 mg per 5 mL, 100 mL

Chloramphenicol

Eye drops 5 mg per mL, 10 mL

Chlorpromazine

Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL

Ciclesonide

Pressurised inhalation 80 micrograms per dose, 120 doses (CFC‑free formulation)

Pressurised inhalation 160 micrograms per dose, 120 doses (CFC‑free formulation)

Ciprofloxacin

Ear drops 3 mg (as hydrochloride) per mL, 5 mL

Citrulline

Tablet 1 g, 300 (Citrulline Easy)

Clarithromycin

Powder for oral liquid 250 mg per 5 mL, 50 mL

Clobetasol

Shampoo containing clobetasol propionate 500 micrograms per mL,
125 mL

Clonazepam

Oral liquid 2.5 mg per mL, 10 mL

Coal tar

Foam 20 mg per g, 100 g

Cromoglycic Acid

Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC‑free formulation)

 

Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC‑free formulation)

Degarelix

Powder for injection 120 mg (as acetate), 2, injection set

Desmopressin

Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL

Dexamethasone

Eye drops 1 mg per mL, 5 mL

Dexamethasone with Framycetin and Gramicidin

Diazepam

Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL

Oral liquid 1 mg in 1 mL, 100 mL

Dorzolamide

Eye drops 20 mg (as hydrochloride) per mL, 5 mL

Dorzolamide with Timolol

Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL

Eformoterol

Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 6 micrograms per dose, 60 doses

Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses

Electrolyte Replacement, Oral

Oral rehydration salts containing glucose 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10

Erythromycin

Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL

Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL

Escitalopram

Oral solution 20 mg (as oxalate) per mL, 15 mL

Esomeprazole and Clarithromycin and Amoxycillin

Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate)

 

Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate)

Ethosuximide

Oral solution 250 mg per 5 mL, 200 mL

Ezetimibe and rosuvastatin

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin
10 mg (as calcium)

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin
20 mg (as calcium)

 

Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin
40 mg (as calcium)

Ferrous Sulfate

Oral liquid 30 mg per mL, 250 mL

Flucloxacillin

Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL

Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL

Fluorometholone

Eye drops 1 mg per mL, 5 mL

Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL

Fluticasone

Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation)

 

Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation)

 

Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation)

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses

Fluticasone furoate with vilanterol

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Fluticasone with eformoterol

Pressurised inhalation containing fluticasone propionate 50 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses

 

Pressurised inhalation containing fluticasone propionate 125 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses

 

Pressurised inhalation containing fluticasone propionate 250 micrograms with eformoterol fumarate dihydrate 10 micrograms per dose, 120 doses

Fluticasone with Salmeterol

Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

 

Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

 

Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation)

 

Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses

Framycetin

Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL

Frusemide

Oral solution 10 mg per mL, 30 mL

Gentamicin

Eye drops 3 mg (as sulfate) per mL, 5 mL

Glyceryl Trinitrate

Tablets 300 micrograms, 100

 

Tablets 600 micrograms, 100

Sublingual spray (pump pack) 400 micrograms per dose, 200 doses

Goserelin and Bicalutamide

Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg

Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 28 tablets bicalutamide 50 mg

Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre‑filled injection syringe and 84 tablets bicalutamide 50 mg

Haloperidol

Oral solution 2 mg per mL, 100 mL

Hyaluronic acid

Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL

 

Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL

Hydrocortisone

Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g

 

Cream containing hydrocortisone acetate 10 mg per g, 50 g

 

Ointment containing hydrocortisone acetate 10 mg per g, 50 g

Hypromellose

Eye drops 3 mg per mL, 15 mL

Eye drops 5 mg per mL, 15 mL

Hypromellose with Carbomer 980

Ocular lubricating gel 3 mg‑2 mg per g, 10 g

Hypromellose with Dextran

Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL

Ketoconazole

Cream 20 mg per g, 30 g

Shampoo 10 mg per g, 100 mL

Shampoo 20 mg per g, 60 mL

Latanoprost

Eye drops 50 micrograms per mL, 2.5 mL

Latanoprost with Timolol

Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL

Leuprorelin and bicalutamide

Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg

 

Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg

 

Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Macrogol 3350

Powder for oral solution 510 g

 

Sachets containing powder for oral solution 13.125 g with electrolytes, 30

 

Sachets containing powder for oral solution 17 g, 30

Mercaptopurine

Oral suspension 20 mg per mL, 100 mL

Metronidazole

Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL

Suppositories 500 mg, 10

Miconazole

Cream containing miconazole nitrate 20 mg per g, 30 g

 

Cream containing miconazole nitrate 20 mg per g, 70 g

 

Powder containing miconazole nitrate 20 mg per g, 30 g

 

Tincture 20 mg per mL, 30 mL

Mifepristone and misoprostol

Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms

Mupirocin

Nasal ointment 20 mg (as calcium) per g, 3 g

Mycophenolic Acid

Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL

Nafarelin

Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses

Naproxen

Oral suspension 125 mg per 5 mL, 474 mL

Nedocromil

Pressurised inhalation containing nedocromil sodium 2 mg per dose, 112 doses
(CFC‑free formulation)

Netupitant with Palonosetron

Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride)

Nicorandil

Tablets 10 mg, 60

Tablets 20 mg, 60

Oestradiol

Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28

 

Transdermal patches 390 micrograms, 8

 

Transdermal patches 750 micrograms (as hemihydrate), 8

 

Transdermal patches 2 mg, 4

 

Transdermal patches 585 micrograms, 8

 

Transdermal patches 1.5 mg (as hemihydrate), 8

 

Transdermal patches 3.8 mg, 4

 

Transdermal patches 780 micrograms, 8

 

Transdermal patches 5.7 mg, 4

 

Transdermal patches 1.17 mg, 8

 

Transdermal patches 3 mg (as hemihydrate), 8

 

Transdermal patches 7.6 mg, 4

 

Transdermal patches 1.56 mg, 8

Oestradiol and Oestradiol with Dydrogesterone

Pack containing 14 tablets oestradiol 1 mg and 14 tablets oestradiol 1 mg with dydrogesterone 10 mg

 

Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg

Oestradiol and Oestradiol with Norethisterone

Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate

 

Pack containing 4 transdermal patches 780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate

Oestradiol with Norethisterone

Transdermal patches containing 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

 

Transdermal patches containing 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

Oestriol

Pessaries 500 micrograms, 15

Vaginal cream 1 mg per g, 15 g

Ondansetron

Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL

Oxybutynin

Transdermal patches 36 mg, 8

Paracetamol

Oral liquid 120 mg per 5 mL, 100 mL

Oral liquid 240 mg per 5 mL, 200 mL

Paraffin

Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g

Peginterferon beta-1a

Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL

Permethrin

Cream 50 mg per g, 30 g

Phenytoin

Oral suspension 30 mg per 5 mL, 500 mL

Pilocarpine

Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL

 

Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL

 

Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL

Pimecrolimus

Cream 10 mg per g, 15 g

Polyethylene Glycol 400 with Propylene Glycol

Eye drops 4 mg‑3 mg per mL, 15 mL

Polyvinyl Alcohol

Eye drops 14 mg per mL, 15 mL

 

Eye drops 14 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)

 

Eye drops 30 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)

Prednisolone

Oral solution 5 mg (as sodium phosphate) per mL, 30 mL

Prednisolone with Phenylephrine

Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL

Quinagolide

Pack containing 3 tablets quinagolide 25 micrograms (as hydrochloride) and 3 tablets quinagolide 50 micrograms (as hydrochloride)

Reteplase

Pack containing 2 vials powder for injection 10 units, 2 single use pre‑filled syringes with solvent, 2 reconstitution spikes and 2 needles

Rifampicin

Syrup 100 mg per 5 mL, 60 mL

Risedronic Acid and Calcium

Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate)

 

Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate)

Risedronic acid and calcium with colecalciferol

Pack containing 4 enteric coated tablets risedronate sodium 35 mg and 24 sachets containing granules of calcium carbonate 2.5 g with colecalciferol 22 micrograms

Risperidone

Oral solution 1 mg per mL, 100 mL

Salbutamol

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20

Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30

Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses
(CFC‑free formulation)

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30

Salmeterol

Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses

Silver sulfadiazine

Cream 10 mg per g, 50 g

Sirolimus

Oral solution 1 mg per mL, 60 mL

Sterculia with Frangula Bark

Granules 620 mg‑80 mg per g, 500 g

Tafluprost

Eye drops 15 micrograms per mL, single dose units 0.3 mL, 30

Testosterone

Transdermal cream 50 mg per mL, 50 mL

Transdermal gel 50 mg in 5 g sachet, 30

Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2

Transdermal patches 12.2 mg, 60

Transdermal patches 24.3 mg, 30

Theophylline

Oral solution 133.3 mg per 25 mL, 500 mL

Timolol

Eye gel 1 mg (as maleate) per g, 5 g

 

Eye drops 5 mg (as maleate) per mL, 5 mL

 

Eye drops (gellan gum solution) 2.5 mg (as maleate) per mL, 2.5 mL

 

Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL

Tiotropium with olodaterol

Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses

Tobramycin

Eye drops 3 mg per mL, 5 mL

Eye ointment 3 mg per g, 3.5 g

Tiotropium

Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)

Tramadol

Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL

Travoprost

Eye drops 40 micrograms per mL, 2.5 mL

Travoprost with Timolol

Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL

Triamcinolone with Neomycin, Gramicidin and Nystatin

Ear drops containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 7.5 mL

Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g

Trimethoprim with Sulfamethoxazole

Paediatric oral suspension 40 mg‑200 mg per 5 mL, 100 mL

Umeclidinium

Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses

Umeclidinium with vilanterol

Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

Varenicline

Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack

 

SCHEDULE 5—LIST OF STANDARD FORMULA PREPARATIONS

Form of pharmaceutical benefit

Standard formula preparations

Creams

Salicylic Acid and Sulfur Aqueous APF

Dusting Powders

Zinc, Starch and Talc APF 15

Zinc, Starch and Talc BPC 1973

Ear Drops

Aluminium Acetate APF

 

Aluminium Acetate BP

 

Sodium Bicarbonate APF

 

Sodium Bicarbonate BP

 

Spirit APF

Eye Drops containing Cocaine Hydrochloride BP

Eye Drops, Other

Eye Lotions

Inhalations

Benzoin and Menthol APF

Menthol APF

Menthol and Eucalyptus BP 1980

Linctuses containing Codeine Phosphate

Codeine APF

Linctuses, Other

Lotions

Aluminium Acetate Aqueous APF

Mixtures containing Codeine Phosphate

Mixtures, Other

Gentian Alkaline APF

 

Kaolin BPC 1968

 

Kaolin and Opium APF 14

 

Magnesium Trisilicate BPC 1968

 

Magnesium Trisilicate and Belladonna BPC 1968

Mixtures for Children containing Codeine Phosphate BP

Mixtures for Children, Other

Mouth Washes

Thymol Compound APF 15

Nasal Instillations

Ointments, Waxes

Benzoic Acid Compound APF

 

Benzoic Acid Compound (extemporaneous formula) BP

 

Boric Acid, Olive Oil and Zinc Oxide QHF

 

Salicylic Acid APF

 

Salicylic Acid (extemporaneous formula) BP

Paints

Podophyllin Compound APF 16

Podophyllin Compound BP

Salicylic Acid APF

Pastes containing Cocaine Hydrochloride

Pastes, Other

Zinc APF

Zinc Compound (extemporaneous formula) BP

Powders for Internal Use

Magnesium Trisilicate BP

Solutions

 

 


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

 

 

 

 

Endnote 2—Abbreviation key

 

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

    /sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

    effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

    effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

    cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

    commenced or to be commenced

 

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

PB 119 of 2008

28 Nov 2008 (F2008L02618)

1 Dec 2008

 

PB 131 of 2008

11 Dec 2008 (F2008L04645)

1 Jan 2009

PB 26 of 2009

18 Mar 2009 (F2009L01117)

1 Apr 2009

PB 38 of 2009

15 Apr 2009 (F2009L01321)

1 May 2009

PB 42 of 2009

11 May 2009 (F2009L01714)

1 June 2009

PB 53 of 2009

11 June 2009 (F2009L02293)

1 July 2009

PB 68 of 2009

10 July 2009 (F2009L02717)

1 Aug 2009

PB 81 of 2009

17 Aug 2009 (F2009L03153)

1 Sept 2009

PB 112 of 2009

20 Nov 2009 (F2009L04263)

1 Dec 2009

PB 122 of 2009

10 Dec 2009 (F2009L04556)

1 Jan 2010

PB 131 of 2009

13 Jan 2010 (F2010L00104)

1 Feb 2010

PB 20 of 2010

17 Mar 2010 (F2010L00678)

1 Apr 2010

as amended by

 

 

 

PB 32 of 2010

30 Mar 2010 (F2010L00775)

31 Mar 2010

PB 39 of 2010

15 Apr 2010 (F2010L00941)

1 May 2010

PB 48 of 2010

21 May 2010 (F2010L01379)

1 June 2010

PB 58 of 2010

21 June 2010 (F2010L01622)

1 July 2010

PB 73 of 2010

19 July 2010 (F2010L02067)

1 Aug 2010

PB 99 of 2010

29 Oct 2010 (F2010L02858)

1 Nov 2010

PB 111 of 2010

30 Nov 2010 (F2010L03128)

1 Dec 2010

PB 121 of 2010

17 Dec 2010 (F2010L03306)

1 Jan 2011

PB 8 of 2011

28 Jan 2011 (F2011L00164)

1 Feb 2011

PB 26 of 2011

28 Mar 2011 (F2011L00509)

1 Apr 2011

PB 37 of 2011

26 May 2011 (F2011L00867)

1 June 2011

PB 52 of 2011

27 July 2011 (F2011L01544)

1 Aug 2011

PB 59 of 2011

29 Aug 2011 (F2011L01764)

1 Sept 2011

PB 68 of 2011

28 Sept 2011 (F2011L01986)

1 Oct 2011

PB 85 of 2011

28 Nov 2011 (F2011L02475)

1 Dec 2011

PB 97 of 2011

19 Dec 2011 (F2011L02736)

1 Jan 2012

PB 15 of 2012

29 Mar 2012 (F2011L00715)

1 Apr 2012

PB 29 of 2012

26 Apr 2012 (F2012L00937)

1 May 2012

PB 34 of 2012

8 May 2012 (F2012L01004)

1 June 2012

PB 38 of 2012

15 June 2012 (F2012L01202)

1 July 2012

PB 46 of 2012

25 July 2012 (F2012L01601)

1 Aug 2012

PB 63 of 2012

22 Aug 2012 (F2012L01732)

1 Sept 2012

PB 75 of 2012

28 Sept 2012 (F2012L01969)

1 Oct 2012

PB 95 of 2012

29 Nov 2012 (F2012L02287)

1 Dec 2012

PB 5 of 2013

21 Jan 2013 (F2013L00071)

22 Jan 2013 (s 2)

PB 9 of 2013

14 Feb 2013 (F2013L00186)

1 Mar 2013 (s 2)

PB 33 of 2013

24 May 2013 (F2013L00840)

1 June 2013 (s 2)

PB 49 of 2013

29 July 2013 (F2013L01459

1 Aug 2013 (s 2)

PB 59 of 2013

15 Aug 2013 (F2013L01578)

1 Sept 2013 (s 2)

PB 80 of 2013

29 Nov 2013 (F2013L02015)

1 Dec 2013 (s 2)

PB 91 of 2013

20 Dec 2013 (F2013L02167)

1 Jan 2014 (s 2)

PB 3 of 2014

10 Jan 2014 (F2014L00050)

1 Feb 2014 (s 2)

PB 10 of 2014

14 Feb 2014 (F2014L00144)

1 Mar 2014 (s 2)

PB 19 of 2014

27 Mar 2014 (F2014L00357)

1 Apr 2014 (s 2)

PB 29 of 2014

11 Apr 2014 (F2014L00401)

1 May 2014 (s 2)

PB 38 of 2014

22 May 2014 (F2014L00593)

1 June 2014 (s 2)

PB 46 of 2014

19 June 2014 (F2014L00761)

1 July 2014 (s 2)

PB 57 of 2014

30 July 2014 (F2014L01052 )

1 Aug 2014 (s 2)

PB 62 of 2014

25 Aug 2014 (F2014L01125)

1 Sept 2014 (s 2)

PB 74 of 2014

26 Sept 2014 (F2014L01256)

1 Oct 2014 (s 2)

PB 83 of 2014

23 Oct 2014 (F2014L01393)

1 Nov 2014 (s 2)

PB 90 of 2014

28 Nov 2014 (F2014L01599)

1 Dec 2014 (s 2)

PB 108 of 2014

22 Dec 2014 (F2014L01772)

1 Jan 2015 (s 2)

PB 2 of 2015

14 Jan 2015 (F2015L00039)

1 Feb 2015 (s 2)

PB 12 of 2015

25 Feb 2015 (F2015L00207)

1 Mar 2015 (s 2)

PB 28 of 2015

26 Mar 2015 (F2015L00338)

1 Apr 2015 (s 2)

PB 41 of 2015

24 Apr 2015 (F2015L00589)

1 May 2015 (s 2)

PB 49 of 2015

29 May 2015 (F2015L00764)

1 June 2015 (s 2)

PB 56 of 2015

1 July 2015
(F2015L01065)

1 July 2015 (s 2)

PB 70 of 2015

31 July 2015 (F2015L01205)

1 Aug 2015 (s 2)

PB 80 of 2015

28 Aug 2015 (F2015L01350)

1 Sept 2015 (s 2)

PB 92 of 2015

30 Sept 2015 (F2015L01539)

1 Oct 2015 (s 2)

PB 109 of 2015

1 Dec 2015
(F2015L01894)

1 Dec 2015 (s 2)

PB 119 of 2015

24 Dec 2015 (F2015L02139)

1 Jan 2016 (s 2)

PB 3 of 2016

1 Feb 2016   (F2016L00077)

1 Feb 2016 (s 2)

PB 20 of 2016

1 Apr 2016
(F2016L00469)

1 Apr 2016 (s 2)

PB 31 of 2016

29 Apr 2016 (F2016L00603)

1 May 2016 (s 2)

PB 44 of 2016

30 May 2016 (F2016L00855)

1 June 2016 (s 2)

PB 53 of 2016

22 June 2016 (F2016L01058)

1 July 2016 (s 2)

PB 65 of 2016

19 July 2016
(F2016L01196)

1 Aug 2016 (s 2)

PB 74 of 2016

18 Aug 2016 (F2016L01298)

1 Sept 2016 (s 2)

PB 108 of 2016

30 Nov 2016 (F2016L01835)

1 Dec 2016 (s 2)

PB 3 of 2017

25 Jan 2017 (F2017L00071)

1 Feb 2017 (s 2)

PB 18 of 2017

30 Mar 2017 (F2017L00355)

1 Apr 2017 (s 2)

PB 28 of 2017

28 Apr 2017 (F2017L00488)

1 May 2017 (s 2)

PB 36 of 2017

31 May 2017 (F2017L00620)

1 June 2017 (s 2)

PB 64 of 2017

30 Aug 2017 (F2017L01109)

1 Sept 2017 (s 2)

PB 73 of 2017

27 Sept 2017 (F2017L01277)

1 Oct 2017 (s 2)

PB 86 of 2017

24 Oct 2017 (F2017L01386)

1 Nov 2017 (s 2)

PB 110 of 2017

18 Dec 2017 (F2017L01628)

1 Jan 2018 (s 2)

PB 3 of 2018

24 Jan 2018 (F2018L00059)

1 Feb 2018 (s 2)

Endnote 4—Amendment history

 

Provision affected

How affected

s 1..........................................

rep LA s 48D

s 2..........................................

rep LA s 48C

s 3..........................................

am PB 59 of 2011; PB 75 of 2012

s 5..........................................

am PB 75 of 2012

s 6..........................................

am PB 75 of 2012

s 9..........................................

am PB 59 of 2011; PB 75 of 2012

Schedule 1

 

Schedule 1..............................

am PB 68 of 2009; PB 37 and 59 of 2011; PB 46 of 2012; PB 70 of 2015; PB 86 of 2017

Schedule 3

 

Schedule 3..............................

am PB 26, 38 and 131 of 2009; PB 52, 59 and 85 of 2011; PB 38 of 2012; PB 5 of 2013; PB 3, 19 and 38 of 2014; PB 80 of 2015; PB 3, 20, 31, 44, 65 and 74 of 2016; PB 3 of 2017; PB 28 of 2017; PB 64 of  2017; PB 73 of 2017

Schedule 4

 

Schedule 4..............................

am PB 131 of 2008; PB 26, 42, 53, 68, 81, 112, 122 and 131 of 2009; PB 20 of 2010 (as am by PB 32 of 2010); PB 39, 48, 58, 73, 99, 111 and 121 of 2010; PB 8, 26, 37, 59, 68 and 97 of 2011; PB 15, 29, 34, 38, 46, 63, 75 and 95 of 2012; PB 9, 33, 49, 59, 80 and 91 of 2013; PB 10, 19, 29, 38, 46, 57, 62, 74, 83, 90 and 108 of 2014; PB 2, 12, 28, 41, 49, 56, 70, 80, 92, 109 and 119 of 2015; PB 20 (Sch 1 item 3 md), 31, 53, 65 and 108 of 2016; PB 3 of 2017; PB 18 of 2017; PB 28 of 2017; PB 36 of 2017; PB 86 of 2017; PB 110 of 2017; PB 3 of 2018